0001237899-20-000001.txt : 20200106
0001237899-20-000001.hdr.sgml : 20200106
20200106160244
ACCESSION NUMBER: 0001237899-20-000001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200102
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SING GEORGE L
CENTRAL INDEX KEY: 0001225471
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 20509611
MAIL ADDRESS:
STREET 1: LANCET CAPITAL
STREET 2: 45 ROCKEFELLER PLAZA STE 2008
CITY: NEW YORK
STATE: NY
ZIP: 10111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2020-01-02
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001225471
SING GEORGE L
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2020-01-02
4
M
0
15000
24.41
A
130095
D
Common Stock
2020-01-02
4
S
0
15000
371.98
D
115095
D
Common Stock
2020-01-02
4
A
0
320
0.0
A
115415
D
Common Stock
3000
I
by Spouse
Common Stock
4500
I
by Spouse/Cust Son
Common Stock
10000
I
by Trust for Son
Non-Qualified Stock Option (right to buy)
24.41
2020-01-02
4
M
0
15000
0.0
D
2020-01-04
Common Stock
15000
0
D
Non-Qualified Stock Option (right to buy)
374.12
2020-01-02
4
A
0
4361
0.0
A
2030-01-02
Common Stock
4361
4361
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 15,000 shares of the Issuer's common stock on January 2, 2020 at prices ranging from $371.98 to $371.99. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 2, 2020.
Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
By: Beverly Dubs as attorney-in-fact For: George L. Sing
2020-01-06